Cullinan Therapeutics to Advance Leukemia Drug into Pivotal Phase 2 Trial After Positive FDA Meeting

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) has received a positive signal from the U.S. Food and Drug Administration (FDA) regarding the development of its acute myeloid leukemia (AML) drug candidate, CLN-049. Following an End-of-Phase 1 meeting, the company announced it will proceed with a potentially registrational Phase 2 study, prompting its shares to rise 1.6% in Tuesday's trading.

FDA Greenlights Pivotal Trial Design

Based on feedback from the FDA, Cullinan plans to initiate the Phase 2 trial for CLN-049 in patients with relapsed or refractory (R/R) AML in the third quarter of 2026. A "potentially registrational" study means its results could form the basis of a future marketing application if successful, representing a significant step toward commercialization.

The trial design, which was discussed with the agency, incorporates a brief dose-optimization phase that will transition seamlessly into a single-arm cohort at the recommended Phase 2 dose. This structure is designed to efficiently gather data on the drug's efficacy and safety.

Clinical Pathway and Next Steps

CLN-049 is a FLT3xCD3 T cell engager designed to direct the patient's own T cells to attack leukemia cells expressing the FLT3 protein, regardless of mutational status. The company previously presented data at the 2025 American Society of Hematology Annual Meeting indicating that the drug demonstrated clinical activity and a manageable safety profile in R/R AML patients.

Ad

Cullinan outlined several upcoming milestones for the program:

• An update from the dose escalation portion of the ongoing study is expected in the fourth quarter of 2026.
• A new Phase 1/2 study will be initiated to evaluate CLN-049 in combination with venetoclax and azacitidine for previously untreated AML patients, expanding the drug's potential application.

Market Context for AML Treatment

Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow. Approximately 23,000 people are diagnosed with AML in the U.S. each year, according to the source material. For patients whose disease has relapsed or is refractory to treatment, the prognosis is poor, with a five-year survival rate of 10% or less, highlighting a significant unmet medical need.

CLN-049 has already been granted both Orphan Drug designation and Fast Track designation by the FDA for the treatment of R/R AML. These designations are intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.